Hepatic uptake of the novel antifungal agent caspofungin

Drug Metabolism and Disposition

Volumn 33, Issue 5, 2005, Pages 676-682

  Sandhu, Punam ^b   Lee, Wooin ^a   Xu, Xin ^b,c   Leake, Brenda F ^a   Yamazaki, Masayo ^b   Stone, Julie A ^b   Lin, Jiunn H ^b   Pearson, Paul G ^b,d   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

^d Dept Pharmacokin Drug Metab A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN A; DOXYCYCLINE; ESTRADIOL 17 GLUCURONIDE; INDOMETACIN; MEVINOLIN; ORGANIC ANION TRANSPORTER; QUINIDINE; TAUROCHOLIC ACID; TETRYLAMMONIUM; URSODEOXYCHOLIC ACID; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; DRUG UPTAKE; GENE OVEREXPRESSION; GENE TARGETING; HELA CELL; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; LIVER; LIVER METABOLISM; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

ADSORPTION; ANIMALS; ANTIFUNGAL AGENTS; CARRIER PROTEINS; HELA CELLS; HUMANS; KB CELLS; KINETICS; LIVER; ORGANIC ANION TRANSPORT POLYPEPTIDE C; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; PERFUSION; PLASMIDS; PROTEIN BINDING; RATS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; TRANSFECTION;

RODENTIA;

EID: 17844402485     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.003244     Document Type: Article

References (23)

1. Abruzzo GK, Flattery AM. Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, et al. (1997) Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 41:2333-2338.
2. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, and Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46:451-457.
3. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, et al. (2000) Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 28:1274-1278.
4. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, et al. (1997) In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2326-2332.
5. Blakely RD, Clark JA, Rudnick G, and Amara SG (1991) Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal Biochem 194:302-308.
6. Cui Y, Konig J, and Keppler D (2001) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60:934-943.
7. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
8. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, and Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2339-2334.
9. Koss T, Bagheri B, Zeana C, Romagnoli MF, and Grossman ME (2002) Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol 46:945-947.
10. Legg B and Rowland M (1987) Cyclosporin: measurement of fraction unbound in plasma. J Pharm Pharmacol 39:599-603.
11. Letscher-Bru V and Herbrecht R (2003) Caspofungin: the first representative of a new antifungal class. J Amimicrob Chemother 51:513-521.
12. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, and Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029.
13. Pang KS (1984) Liver perfusion studies in drug metabolism and drug toxicity, in Drug Metabolism and Drug Toxicity (Mitchell JR and Horning MG eds) pp 331-352, Raven Press, New York.
14. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, and Pearson PG (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits and monkeys. Amimicrob Agents Chemother 48:1272-1280.
15. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, et al. (2002) Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Amimicrob Agents Chemother 46:739-745.
16. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, et al. (2004a) Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306-4314.
17. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, et al. (2004b) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815-823.
18. Tirana RG, Leake BF, Merino G, and Kim RB (2001) Polymorphisms in OATP1B1: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276:35669-35675.
19. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
20. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
21. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornley OA, Bourque MR, Lupinacci RJ, Sable CA, et al. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402.
22. Xu X, DeLuna F, Cartwright M, Huber C, Frank J, Chiba M, and Lin JH (1996) A two-step process for the hepatic uptake of L-743,872 in rats: an initial rapid adsorption on the cell surface followed by a slow transport across the cell membrane. Pharm Res (NY) 13:S454.
23. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein- mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.